Linacord 5 Tablet contains Linagliptin 5 mg, an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, indicated for the management of type 2 diabetes mellitus. Linagliptin works by selectively inhibiting the DPP-4 enzyme, thereby increasing the levels of incretin hormones such as GLP-1 and GIP, which enhance glucose-dependent insulin secretion and suppress glucagon release, leading to improved glycemic control. Linacord 5 is prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, to achieve optimal blood glucose regulation. The drug is characterized by a favorable pharmacokinetic profile, including minimal renal excretion, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Common adverse effects are generally mild and may include nasopharyngitis, headache, and upper respiratory tract infections. Linacord 5 should be used cautiously in patients with a history of pancreatitis, and therapy should be discontinued if pancreatitis is suspected. Regular monitoring of glycemic parameters and renal function is recommended during treatment. Linacord 5 Tablet offers an effective and well-tolerated option for improving glycemic control in adults with type 2 diabetes mellitus.